Registry of Patients With Rheumatoid Arthritis Exposed to Golimumab (Go-Compl-Ar): Review and Analysis of Compliance in Colombia
Phase of Trial: Phase IV
Latest Information Update: 15 Feb 2017
At a glance
- Drugs Golimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms Go-Compl-Ar
- Sponsors Janssen-Cilag
- 10 Jun 2017 Biomarkers information updated
- 10 Feb 2017 Status changed from recruiting to discontinued.
- 21 Dec 2016 Planned End Date changed from 1 Feb 2019 to 1 Jul 2018.